Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F15%3A00059500" target="_blank" >RIV/00023001:_____/15:00059500 - isvavai.cz</a>

Výsledek na webu

<a href="http://progressintransplantation.com/doi/10.7182/pit2015934" target="_blank" >http://progressintransplantation.com/doi/10.7182/pit2015934</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7182/pit2015934" target="_blank" >10.7182/pit2015934</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report

Popis výsledku v původním jazyce

Evidence regarding the use of bortezomib-containing schemes in primary treatment of antibody-mediated rejection in heart transplant recipients is scarce. This case report presents the clinical experience with upstream use of bortezomib in primary treatment of early antibody-mediated rejection in an adult heart transplant recipient. Two cycles of bortezomib together with methylprednisolone, immunoadsorption, rituximab, and supplementary doses of intravenous immunoglobulin G reversed signs of heart failure, production of donor-specific antibodies, and findings of antibody-mediated rejection in biopsy. This treatment regimen was tolerated with only mild hematologic toxicity and proved to be successful during a 12-month follow-up. Primary treatment with a bortezomib-containing regimen appears to be a new therapeutic option for severe antibody-mediated rejection in heart transplant recipients. However, the efficacy and safety of this treatment need to be tested in prospective trials. (C) 2015 NATCO, The Organization for Transplant Professionals

Název v anglickém jazyce

Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report

Popis výsledku anglicky

Evidence regarding the use of bortezomib-containing schemes in primary treatment of antibody-mediated rejection in heart transplant recipients is scarce. This case report presents the clinical experience with upstream use of bortezomib in primary treatment of early antibody-mediated rejection in an adult heart transplant recipient. Two cycles of bortezomib together with methylprednisolone, immunoadsorption, rituximab, and supplementary doses of intravenous immunoglobulin G reversed signs of heart failure, production of donor-specific antibodies, and findings of antibody-mediated rejection in biopsy. This treatment regimen was tolerated with only mild hematologic toxicity and proved to be successful during a 12-month follow-up. Primary treatment with a bortezomib-containing regimen appears to be a new therapeutic option for severe antibody-mediated rejection in heart transplant recipients. However, the efficacy and safety of this treatment need to be tested in prospective trials. (C) 2015 NATCO, The Organization for Transplant Professionals

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Progress in Transplantation

ISSN

1526-9248

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

147-152

Kód UT WoS článku

000356105200008

EID výsledku v databázi Scopus

—